Drug Profile
Vadadustat - Akebia Therapeutics
Alternative Names: AKB-6548; MT 6548; PG 1016548; VAFSEO; VafseoLatest Information Update: 21 Mar 2024
Price :
$50
*
At a glance
- Originator Procter & Gamble
- Developer Akebia Therapeutics; Mitsubishi Tanabe Pharma Corporation; Otsuka Pharmaceutical
- Class Acetic acids; Amides; Antianaemics; Antivirals; Chlorobenzenes; Chlorophenols; Pyridines; Small molecules; Urologics
- Mechanism of Action Hypoxia-inducible factor-proline dioxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Anaemia
- Phase II Renal failure; SARS-CoV-2 acute respiratory disease
Most Recent Events
- 31 Dec 2023 Akebia Therapeutics has patent protection for composition of matter, polymorph, method of treating anaemia, and pharmaceutical compositions of vadadustat in USA and issued or pending patents in countries worldwide
- 31 Dec 2023 Akebia Therapeutics has pending patents for processes for manufacturing vadadustat, dosing regimens, formulations, and aspects relating to the treatment of Anaemia in countries worldwide
- 14 Dec 2023 Akebia Therapeutics completes the phase IIIFO2CUS trial in Anaemia (Treatment-experienced) (PO, Tablet) (NCT04707768)